News & Updates

A 23-year longitudinal follow-up in a population-based cohort has shown a slowly progressive trend in nonalcoholic fatty liver disease (NAFLD), with liver-related outcomes affecting only a small number of people, reports a recent study.

The addition of vebicorvir to entecavir in treatment-naïve patients with chronic hepatitis B virus (HBV) infection provides further antiviral activity, with a positive safety and tolerability profile, results of a phase II trial have shown.

Adherence to a freshwater fish-based diet helps regulate the gut microbiota and its metabolites, suggesting benefits in individuals with nonalcoholic fatty liver disease (NAFLD), reveals a study.

Ezetimibe plus rosuvastatin reduces liver fat in people with nonalcoholic fatty liver disease (NAFLD) in the randomized, active-controlled ESSENTIAL trial.

Exercise interventions may result in positive outcomes on muscular or cardiorespiratory fitness and quality of life in patients with advanced liver disease, suggest the results of a systematic review.

Treatment with the nucleos(t)ide analogue (NUC) tenofovir alafenamide (TAF) for 2 years leads to improvements in liver stiffness among patients with chronic hepatitis B (CHB), including those with advanced liver fibrosis, according to a study presented at the IDWeek 2022 in Washington, DC, US.

Among people living with HIV (PLHIV), immunization with a hepatitis B surface antigen (HBsAg)-based vaccine adjuvanted with a toll-like receptor (TLR)-9 agonist can induce a 100-percent seroprotection rate, according to a study presented at the recently concluded Virtual ID Week 2022.

Liver enzymes play a partial role in the relationship between exposure to particulate matter (PM) and risk of diabetes, indicating the involvement of lipid accumulation, oxidative stress, and chronic inflammation in the liver in its pathogenesis, reports a recent study.